Topics

Latest Cholesterol NewsRSS

15:59 EDT 15th September 2019 | BioPortfolio

The Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid Completes Patient Enrolment

Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver that is currently undergoing regulatory review The CLEAR cardiovascular outcomes trial has completed enrolment with 14,032 patients and is expected to report results in the second half of 2022   Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announ...

Aurobindo recalls 2,352 bottles of statins from US market

Aurobindoâs US subsidiary issues a voluntary recall of statin tablets, after the bottles were found to be incorrectly labelled.

Combination treatment with n-3 polyunsaturated fatty acids and ursodeoxycholic acid dissolves cholesterol gallstones in mice

Crow Cholesterol Climbs After Chomping Cheeseburgers http://dlvr.it/RCQb4D pic.twitter.com/pt72PGFTSl

Crow Cholesterol Climbs After Chomping Cheeseburgers http://dlvr.it/RCQb4D  pic.twitter.com/pt72PGFTSl

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'

Source: Streetwise Reports   09/04/2019 The study data and their implications are provided in a BTIG report.In an Aug. 29 research note, BTIG analyst Thomas Shrader reported that just released topline data are "as hoped" from Esperion Therapeutics Inc.'s (ESPR:NASDAQ) Phase 2 trial of bempedoic acid-ezetimibe combination therapy in patients with hypercholesterolemia an...

A primary care physician’s decisions are questioned and second-guessed daily

A 67-year-old woman with a high-stress job had a vigorous disagreement with her neighbors last week. She developed severe substernal chest pain and called 911 fearing a heart attack. She is thin, has never smoked, has normal blood pressure and normal cholesterol. She is not a diabetic and runs on a treadmill for two hours […] Find jobs at Careers by KevinMD.com. Search thousands of physici...

International Atherosclerosis Society & Residual Risk Reduction Initiative Publish Consensus Statement on New Treatment for Residual Cardiovascular Risk

MILAN and BASEL, Switzerland, Sept. 3, 2019 /PRNewswire/ -- A new highly selective treatment, a peroxisome proliferator-activated receptor alpha modulator (SPPARM-alpha) agonist, may help to address the gap in managing the residual risk of heart attacks and strokes in high-risk patients, according to over 50 world-leading experts from the International

Cholesterol levels reduced 54% with The Medicines Company's long-acting PCSK9 inhibitor inclisiran; CEO open to "value-based" pricing http://www.firstwordpharma.com/node/1663216?tsid=28®ion_id=6#axzz5yHmTkGKf …

Cholesterol levels reduced 54% with The Medicines Company's long-acting PCSK9 inhibitor inclisiran; CEO open to "value-based" pricing http://www.firstwordpharma.com/node/1663216?tsid=28&region_id=6#axzz5yHmTkGKf …

Medicines Co.'s cholesterol drug looks good to take on PCSK9 rivals

Data show Inclisiran more or less matched Repatha and Praluent on cholesterol lowering, but the drug will need a smart launch, and possibly a partner, to compete.

A Community-Based Intervention for Reducing Hypertension and Cardiovascular Disease Risk

In the HOPE 4 trial, an intervention led by nonphysician health workers lowered blood pressure and cholesterol, while increasing medication adherence and healthy behaviors.

The Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

-  Inclisiran achieved 54% LDL-C lowering with time-adjusted reductions of 50% sustained over 18 months of treatment -  ORION-11 study demonstrates inclisiran’s excellent safety profile, including no treatment-related liver or renal abnormalities -  Full study results presented during late-breaking science session at ESC Congress 2019 -  The Medicines Company to host investor conferen...

Weight Loss And Cardiovascular Benefits With Alternate Day Fasting: Study

After analyzing the effects of four-weeks of alternate day fasting, the researchers found that it was more than just a weight loss program. The results showed amazing positive impacts on cholesterol, blood pressure, and abdominal fat.

U.S. District Court Invalidates Amgen Patents Over Cholesterol Med

In an ongoing battle between Regeneron Pharmaceuticals and Sanofi versus Amgen over PCSK9 inhibitors to treat high cholesterol, a U.S. district court invalidated Amgen’s patents for Repatha.

STAT Plus: Pharmalittle: National Academies opioid panel had conflicts; Amgen loses round in patent wars

A U.S. judge set aside a jury verdict that found Amgen patents on its Repatha cholesterol drug were valid, handing a victory to Regeneron Pharmaceuticals and Sanofi.

Positive Results Highlight Potential of Bempedoic Acid / Ezetimibe Combination for Hypercholesterolaemia with Type 2 Diabetes

 Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver Bempedoic acid / ezetimibe FDC achieved a robust 40% reduction in LDL-C (placebo-corrected) and reduced hsCRP by 25% in this Phase 2 study without worsening glycaemic parameters Overall adverse events for bempedoic acid / ezetimibe FDC were comparable to placebo Daiic...

Stopping Statins for Primary Prevention in the Elderly Poses Risks

In a large observational study, statin discontinuers were vulnerable to later cardiovascular hospitalizations.

Amgen patents on Repatha invalid, judge rules in reversal

The decision by Judge Richard Andrews overturns a February jury verdict which had affirmed two patents held by Amgen on its cholesterol drug Repatha. 

Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Cholesterol Management

Multiple Papers and Presentations Highlight REDUCE-IT and Vascepa®Potential Mechanisms of Action of Vascepa Becoming Better Understood American Heart Association References REDUCE-IT in Scientific Advisory BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, tod...

The Medicines Company's PCSK9 Inhibitor for Cholesterol Looks Good in Phase III http://dlvr.it/RBx3gJ pic.twitter.com/3dgtH0nAIC

The Medicines Company's PCSK9 Inhibitor for Cholesterol Looks Good in Phase III http://dlvr.it/RBx3gJ  pic.twitter.com/3dgtH0nAIC

The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran

­ ORION-11 study met all primary and secondary efficacy endpoints with efficacy consistent with Phase 1 and 2 studies ­ Safety profile of inclisiran was at least as favorable as in ORION-1 Phase 2 and ORION-3 open-label extension studies ­ Detailed data will be presented during late-breaking science session at ESC Congress 2019 on Monday, September 2, 8:30 am CET / 2:30 am EDT ­ The Med...

The Medicines Company's PCSK9 Inhibitor for Cholesterol Looks Good in Phase III

Inclisiran is a PCSK9 inhibitor, a class of anti-cholesterol medications used to treat patients who don’t respond to statins.

The Impact of Statin Type on Hepatocellular Carcinoma Risk

In patients with chronic viral hepatitis, only lipophilic statin use, and not hydrophilic statin use, significantly lowered 10-year HCC risk.

Can the cardiac risk of red meat be measured? And is it useful?

Prevention of heart disease has centered on smoking cessation, controlling blood pressure, achieving an appropriate weight, regular exercise, control of blood sugar, and control of your cholesterol.  Despite addressing and controlling these items, individuals still have heart attacks and strokes and vascular events. Researchers are now directing their attention to a dietary metabolite of red [...

Sticky meshworks of DNA and proteins extruded by neutrophils act as the glue that binds together calcium and cholesterol crystals during gallstone formation, scientists in Germany report: http://ow.ly/dGPG50vC2tx 

Sticky meshworks of DNA and proteins extruded by neutrophils act as the glue that binds together calcium and cholesterol crystals during gallstone formation, scientists in Germany report: http://ow.ly/dGPG50vC2tx 

Should We Pretreat the Donor Heart with a Statin?

Biomarkers indicate less myocardial injury with simvastatin pretreatment.

Quick Search

review and buy Cholesterol market research data and corporate reports here